



Synthesis of H-bonding probes of $\alpha 7$ nAChR agonist selectivity

Jingyi Wang^a, Roger L. Papke^b, Nicole A. Horenstein^{a,*}

^a Department of Chemistry, University of Florida, PO Box 117200, Gainesville, FL 32611-7200, USA

^b Department of Pharmacology and Therapeutics, University of Florida, PO Box 100267 Gainesville, FL 32610-0267, USA

ARTICLE INFO

Article history:

Received 26 September 2008

Revised 8 November 2008

Accepted 12 November 2008

Available online 18 November 2008

Keywords:

Nicotinic
Acetylcholine
Receptor
Agonist
Synthesis
Anabaseine
H-bond

ABSTRACT

The $\alpha 7$ subtype of the nicotinic acetylcholine receptor (nAChR) is the target of studies aimed at identifying features that will lead to the development of selective therapeutics. Five arylidene anabaseines, three with pyridine rings and two with the pyrrole rings, were synthesized in 35–65% yield via aldol condensation. The compounds are homologs of benzylidene anabaseine and were chosen for synthesis because they provide either a hydrogen bond acceptor (pyridines) or hydrogen bond donor (pyrroles) that may interact with the receptor within the benzylidene selectivity motif. Initial analysis of the new compounds at 100 μ M concentration reveal that the two pyrrole anabaseines are good partial agonists of the $\alpha 7$ nAChR, having 40% of the efficacy of ACh, efficacy comparable to 4OH-GTS-21, and dramatically enhanced efficacy relative to the 2- and 4-pyridinyl compounds. The pyrrole compounds were confirmed to be $\alpha 7$ selective, displaying preference for this receptor over muscle and heteromeric neuronal receptor subtypes.

© 2008 Elsevier Ltd. All rights reserved.

Nicotinic acetylcholine receptors (nAChRs) are pentameric ligand-gated ion channels locating in the cell membrane, which allow cations to flow through upon activation.^{1,2} Although primarily expressed in muscle cells and neurons they are also expressed in glia and non neuronal tissues.³ In the brain, heteromeric $\alpha 4\beta 2$ and homomeric $\alpha 7$ subtype are the two major nAChRs: the first one has high binding affinity with acetylcholine and nicotine; the latter one can bind with α -bungarotoxin tightly. Though $\alpha 4\beta 2$ receptors may be the most prevalent nAChRs subtype in the brain,^{4,5} $\alpha 7$ nAChRs have been implicated as influential in neuroprotection, attentional and cognitive enhancement, and inflammatory signaling inhibition. Therefore, selective $\alpha 7$ nAChR agonists are of interest for treatment of Alzheimer's disease, schizophrenia and inflammatory disorders.^{6–8}

Targeting $\alpha 7$ receptors for either inflammation or CNS disorders relies on the development of selective agents so that other nicotinic receptor subtypes are not affected, possibly alleviating serious side effects such as autonomic dysfunction, seizures and drug dependency.^{9–11} Previous studies have shown that functionalization of non selective nAChR agonists can confer $\alpha 7$ selectivity.^{1,12,13} For example, the nAChR agonist anabaseine binds with nAChRs tightly, yet nonselectively with regard to subtype. With an extended hydrophobic group, benzylidene anabaseine (BA, **1**, Fig. 1) exhibits $\alpha 7$ selectivity.¹² We have attributed this selectivity to the interaction of the hydrophobic benzylidene ring with a comple-

mentary recognition site in the $\alpha 7$ receptor, termed the benzylidene motif.¹⁴ Superimposed on this effect, is the interaction between aryl substituents and residues within the benzylidene motif. For example, 3-(4-hydroxy,2-methoxybenzylidene) anabaseine (4-OH GTS-21), **2** (Fig. 1), is a good nAChR partial agonist with high $\alpha 7$ selectivity in both human and rat.¹⁵ Varying the ring substituents of BA compounds will result in changes of the agonists potency and efficacy.^{12,16} A general trend appears to be that polar substituents such as hydroxyl, amino, or methoxy groups tend to give more efficacious agonists.^{12,17} We considered the possibility that these polar groups undergo favorable hydrogen bonding interactions with the receptor, but dissecting the interaction is problematic because hydroxyl and amino groups are both hydrogen bond acceptors and donors. To simplify the analysis, we sought to characterize agonists where the substituents hydrogen bonding interactions could only be H-bond donating or only H-bond accepting, but not both at the same time. Figure 1 presents three novel pyridinyl methylene anabaseines (H-bond acceptor only), **3a–c**, and two pyrrol-3-yl methylene anabaseines (H-bond donor only), **4a,b**, that we synthesized and screened as agonists for different types of nAChRs ($\alpha 7$, $\alpha 4\beta 2$, $\alpha 3\beta 4$, $\alpha 1\beta 1\epsilon\delta$).

Most starting materials and reagents for the synthesis were purchased from Sigma–Aldrich or Fischer Scientific. However, we synthesized pyrrole-3-carboxylaldehyde and anabaseine by modifications of the reported methods.^{18,19} Thus, 3-pyrrole carboxaldehyde (**5b**) was synthesized in 22% yield from the triflic acid catalyzed equilibration of 2-pyrrole carboxaldehyde (**5a**). We omitted the tedious continuous extraction step, and found that two

* Corresponding author. Tel.: +1 352 392 9859; fax: +1 352 846 2095.
E-mail address: horen@chem.ufl.edu (N.A. Horenstein).





Figure 1. Arylidene anabaseines. Benzylidene anabaseine (BA, **1**); 4-OH GTS-21, **2**; pyridinyl methylene anabaseines, **3a–c**; pyrrolyl methylene anabaseine, **4a,b**. Whereas 4OH-GTS-21 presents a complex pattern of H-bond donation and acceptor function, compounds **3** and **4** are either H-bond donors or acceptors, respectively.

consecutive chromatographic steps, a dry silica column followed by a normal silica gel column, were required to purify the crude product (both eluted with $\text{CH}_2\text{Cl}_2/\text{EtOAc}$ at 12:1 ratio).¹⁸


Anabaseine was synthesized as shown in Scheme 1. The gram scale synthesis of anabaseine utilized a mixed Claisen type condensation between N-protected piperidinone **8** and ethyl nicotinate.²⁰ The synthesis of **8** proceeded in low yields, so we sought to optimize the Mannich reaction of valerolactam **7** leading to N-protected **8**. Substitution of paraformaldehyde for aqueous formaldehyde and use of a Dean-Stark trap led to protected **8** in 37% yield after chromatography (silica, $\text{CH}_2\text{Cl}_2/\text{CH}_3\text{OH}$, 15:1).²¹

Mixed Claisen condensation of 1-(diethylaminomethyl)-2-piperidone **8** and ethyl nicotinate afforded the sodium salt, **9**, in 37% yield. Conversion of **9** to anabaseine dihydrochloride was achieved by refluxing in a 5:1 concentrated HCl/acetone mixture. After recrystallization from absolute ethanol, we obtained anabaseine dihydrochloride salt **10** as a white solid in 49% yield.

The general method for synthesis of benzylidene anabaseines and aryl analogs involves aldol-type condensation between an aromatic aldehyde and anabaseine, presumably via its enamine form. Though the reaction may be catalyzed by acid, for example, HCl, conjugate acid/base systems such as acetic acid/acetate can be utilized for aromatic carboxaldehydes with strong electron withdrawing groups.²² Thus, condensation of anabaseine dihydrochloride (or anabaseine dihydrobromide) and pyridine carboxaldehydes or pyrrole carboxaldehydes in methanolic solution optimally produced **3a–c** and **4a,b** in the presence of acetic acid and sodium acetate (mole ratio: 3–1) at room temperature (Scheme 2). It was important to conduct these reactions in inert atmosphere (N_2 or Ar) to minimize side product formation. Reactions for generating **3a–c** were finished within 12 h. The syntheses of **4a,b** required longer reaction times with the less reactive



Scheme 1. Synthesis of anabaseine.



Scheme 2. Synthesis of pyridinyl methylene anabaseine and pyrrolyl methylene anabaseine: **6a**, **6b** and **6c** refer to ortho, meta, para pyridine carboxylaldehyde, respectively; **5a** and **5b** refer to 2- and 3-pyrrole carboxylaldehyde, respectively.

pyrrole carboxaldehydes; 24 h for compound **4a** and 96 h for compound **4b**. Although some aldol condensation reactions can require heat to effect dehydration,²³ double bond formation can often be readily achieved at room temperature. In the present system with pyridine and pyrrole carboxaldehydes, higher temperature tends to adversely affect the yields for condensation. For example, in the synthesis of **3a**, running the reaction at 60, 40 and 25 °C gave 17%, 34% and 58% yields, respectively. Compounds **3a–c** and **4a,b** were carefully purified by silica column chromatography, using $\text{CH}_2\text{Cl}_2/\text{CH}_3\text{OH}$ or $\text{CH}_2\text{Cl}_2/i\text{PrOH}$ as eluent. It was found that $\text{CH}_2\text{Cl}_2/i\text{PrOH}$ was the superior choice for purification of **3c**. The yields for the five compounds were as follows: **3a**, 58%; **3b**, 50%; **3c**, 65%; **4a**, 39%; **4b**, 35%. The E-double bond geometry for **3a–c** and **4a,b** were confirmed by NOESY (Fig. 2). For **3a–c**, irradiation of H6 resulted in enhancement of both H2 and H4, which would only arise from the E-isomer of **3**. Moreover, interaction of the pyridine ring's hydrogen with H5 can also be seen in all of the three **3** isomers. In the case of the pyrrole compounds **4a,b**, irradiating H5 produced a positive NOE on H8 of the pyrrole ring, leading to confirmation of the E-olefin geometry for compounds **4a** and **4b**. MOPAC semi-empirical calculations reveal that the two aromatic rings found in compounds **3** or **4** can π -stack face to face in the Z-isomer. This still doesn't compensate for other destabilizing effects: the Z-isomers for compounds **3** and **4** are all higher in energy than the E-isomers by more than 4 kcal/mol.




Figure 2. NOE enhancement used for assigning the olefin geometry of **3a–c** and **4a, 4b**.

The agonist activity of compounds **3a–c** and **4a,b** was studied in *Xenopus* oocytes expressing mRNAs corresponding to $\alpha 1\beta 1\epsilon\delta$, $\alpha 3\beta 4$, $\alpha 4\beta 2$ or $\alpha 7$ subunits of nAChRs. Compounds were screened at a concentration of 100 μM . Non- $\alpha 7$ receptors were not activated by any of the compounds, with the possible exception of **4b**/ $\alpha 3\beta 4$ which showed very weak (5%) activation relative to control ACh. Interestingly, the pyrrole H-bond donor compounds **4a,b** proved to be good partial agonists with 40% activation relative to ACh with potencies only 2- to 3-fold lower than benzylidene anabaseines such as 2MeO4OHBA (4OH-GTS-21) with comparable efficacy.²⁴ It is also noteworthy that compared to the 'parent' unsubstituted benzylidene anabaseine, **1**, compounds **4a,b** are almost four times more efficacious.¹² Pyridine **3b** produced comparable activation ($\sim 35\%$ ACh maximum) but was approximately 10-fold less potent ($\text{ED}_{50} \approx 100 \mu\text{M}$), while **3a** and **3c** were very weak, producing less than 20% of the ACh response at a concentration of 1 mM. In summary, the results suggest that H-bond donation by substituents on

the extended hydrophobic group of BA analogs leads to preferential activation of the $\alpha 7$ nAChR subtype. Further studies aimed at the detailed characterization of the electrophysiology of these compounds will be reported elsewhere.²⁵

Acknowledgments

This work was supported by Grant R01 GM57481. We thank Dr. I. Ghiviriga for help with the NOESY experiments.

References and notes

- Dani, J. A.; Bertrand, D. *Ann. Rev. Pharmacol. Toxicol.* **2007**, *47*, 699.
- Romanelli, M. N.; Gratteri, P.; Guandalini, L.; Martini, E.; Bonaccini, C.; Gualtieri, F. *Chem. Med. Chem.* **2007**, *2*, 746.
- Sharma, G.; Vijayaraghavan, S. *J. Neurobiol.* **2002**, *53*, 524.
- Whiting, P. J.; Lindstrom, J. M. *J. Neurosci.* **1988**, *8*, 3395.
- Flores, C. M.; Rogers, S. W.; Pabreza, L. A.; Wolfe, B. B.; Kellar, K. J. *Mol. Pharmacol.* **1992**, *41*, 31.
- Carson, R.; Craig, D.; McGuinness, B.; Johnston, J. A.; O'Neil, F. A.; Passmore, A. P.; Ritchie, C. W. *J. Med. Genet.* **2008**, *45*, 244.
- Waldo, M. C.; Adler, L. E.; Leonard, S.; Olincy, A.; Ross, R. G.; Harris, J. G.; Freedman, R. *Biol. Psychiatry* **2000**, *47*, 231.
- De Jonge, W. J.; Ulloa, L. *Brit. J. Pharmacol.* **2007**, *151*, 915.
- Franceschini, D.; Orr-Urtreger, A.; Yu, W.; Mackey, L. Y.; Bond, R. A.; Armstrong, D.; Patrick, J. W.; Beaudet, A. L.; De Biasi, M. *Behav. Brain Res.* **2000**, *113*, 3.
- Damaj, M. I.; Glassco, W.; Dukat, M.; Martin, B. R. *J. Pharmacol. Exp. Ther.* **1999**, *291*, 1284.
- Damaj, M. I.; Kao, W.; Martin, B. R. *J. Pharmacol. Exp. Ther.* **2003**, *307*, 526.
- Papke, R. L.; Meyer, E. M.; Lavieri, S.; Bollampally, S. R.; Papke, T. A. S.; Horenstein, N. A.; Itoh, Y.; Papke, J. K. P. *Neuropharmacology* **2004**, *46*, 1023.
- Leonik, F. M.; Papke, R. L.; Horenstein, N. A. *Bioorg. Med. Chem. Lett.* **2007**, *17*, 1520.
- Horenstein, N. A.; Leonik, F. M.; Papke, R. L. *Mol. Pharmacol.* **2008**, *74*, 1496.
- Meyer, E. M.; Tay, E. T.; Papke, R. L.; Meyers, C.; Huang, G. L.; DeFiebre, C. M. *Brain Res.* **1997**, *768*, 49.
- Kem, W. R.; Mahnir, V. M.; Prokai, L.; Papke, R. L.; Cao, X.; LeFrancois, S.; Wildeboer, K.; Prokai-Tatrai, K. *Mol. Pharmacol.* **2004**, *65*, 56.
- Porter-Papke, J.; Soti, F. *Mol. Pharmacol.* **2004**, *65*, 56.
- Papke, R. L.; Kem, W. R.; Horenstein, N. A., unpublished results.
- Carson, J. R.; Davis, N. M. *J. Org. Chem.* **1981**, *46*, 839.
- Zoltewicz, John A.; Cruskie, Michael P., Jr. *OPPI BRIEFS* **1995**, *27*, 510.
- Katritzky, A. R.; Suzuki, K.; He, H. *J. Org. Chem.* **2002**, *67*, 8224.
- Zoltewicz, J. A.; Prokai-Tatrai, K.; Bloom, L.; Kem, W. R. *Heterocycles* **1993**, *35*, 171.
- Nielsen, A. T.; Houlihan, W. J. *Org. React.* **1968**, *16*, 1.
- Papke, R. L.; Porter-Papke, J. K. *Br. J. Pharmacol.* **2002**, *137*, 49.
- As pointed out by a reviewer, the impact of pyrrole ring size on the activity of **4a,b** relative to 6-membered ring compounds remains an area for investigation.